MyeloMATCH Master Screening and Reassessment Protocol for Adults with Myeloid Cancer Assigning to Targeted Treatment Studies or Standard Care Pathway

What this Trial Is About

The Master Screening and Reassessment Protocol MSRP for the NCI MyeloMATCH clinical trials focuses on patients with myeloid cancers, including acute myeloid leukemia AML and myelodysplastic syndrome MDS. The study evaluates the use of a screening tool and specific laboratory tests, including rapid genetic testing of bone marrow and blood, to better identify biomarkers that can guide treatment decisions. The goal is to improve the ability to assign participants to targeted treatment studies or to continue standard care through a Tier Advancement Pathway TAP. Participants undergo bone marrow aspiration and blood collection for biomarker testing. Based on their mutational profiles, patients may be assigned to specific treatment substudies testing therapies tailored to their cancer or placed on TAP if no targeted treatment is available. The study includes various treatment regimens involving drugs such as azacitidine, venetoclax, daunorubicin, and others administered via intravenous, oral, or subcutaneous routes. Screening also includes echocardiography or multigated acquisition scans to assess heart function. Throughout the study, participants have ongoing bone marrow biopsies and aspirations, blood sample collections, and additional imaging such as chest x-rays, PET, or CT scans as needed. Researchers monitor treatment assignment timing, treatment responses, adverse events, minimal residual disease, and patient survival. The study aims to maintain access to investigational treatments and collect specimens for translational research. The total duration varies by treatment assignment and disease progression, with continuous monitoring throughout.

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)